Tags

Type your tag names separated by a space and hit enter

Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
PLoS One. 2013; 8(8):e71594.Plos

Abstract

X-linked severe combined immunodeficiency (SCID-X1) is an inherited genetic immunodeficiency associated with mutations in the common cytokine receptor γ chain (γc) gene, and characterized by a complete defect of T and natural killer (NK) cells. Gene therapy for SCID-X1 using conventional retroviral (RV) vectors carrying the γc gene results in the successful reconstitution of T cell immunity. However, the high incidence of vector-mediated T cell leukemia, caused by vector insertion near or within cancer-related genes has been a serious problem. In this study, we established a gene therapy model of mouse SCID-X1 using a modified foamy virus (FV) vector expressing human γc. Analysis of vector integration in a human T cell line demonstrated that the FV vector integration sites were significantly less likely to be located within or near transcriptional start sites than RV vector integration sites. To evaluate the therapeutic efficacy, bone marrow cells from γc-knockout (γc-KO) mice were infected with the FV vector and transplanted into γc-KO mice. Transplantation of the FV-treated cells resulted in the successful reconstitution of functionally active T and B cells. These data suggest that FV vectors can be effective and may be safer than conventional RV vectors for gene therapy for SCID-X1.

Authors+Show Affiliations

Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan ; Department of Pediatrics, Tohoku University Graduate School of Medicine, Sendai, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23990961

Citation

Horino, Satoshi, et al. "Gene Therapy Model of X-linked Severe Combined Immunodeficiency Using a Modified Foamy Virus Vector." PloS One, vol. 8, no. 8, 2013, pp. e71594.
Horino S, Uchiyama T, So T, et al. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector. PLoS ONE. 2013;8(8):e71594.
Horino, S., Uchiyama, T., So, T., Nagashima, H., Sun, S. L., Sato, M., Asao, A., Haji, Y., Sasahara, Y., Candotti, F., Tsuchiya, S., Kure, S., Sugamura, K., & Ishii, N. (2013). Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector. PloS One, 8(8), e71594. https://doi.org/10.1371/journal.pone.0071594
Horino S, et al. Gene Therapy Model of X-linked Severe Combined Immunodeficiency Using a Modified Foamy Virus Vector. PLoS ONE. 2013;8(8):e71594. PubMed PMID: 23990961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector. AU - Horino,Satoshi, AU - Uchiyama,Toru, AU - So,Takanori, AU - Nagashima,Hiroyuki, AU - Sun,Shu-Lan, AU - Sato,Miki, AU - Asao,Atsuko, AU - Haji,Yoichi, AU - Sasahara,Yoji, AU - Candotti,Fabio, AU - Tsuchiya,Shigeru, AU - Kure,Shigeo, AU - Sugamura,Kazuo, AU - Ishii,Naoto, Y1 - 2013/08/21/ PY - 2013/06/03/received PY - 2013/07/08/accepted PY - 2013/8/31/entrez PY - 2013/8/31/pubmed PY - 2014/4/23/medline SP - e71594 EP - e71594 JF - PloS one JO - PLoS ONE VL - 8 IS - 8 N2 - X-linked severe combined immunodeficiency (SCID-X1) is an inherited genetic immunodeficiency associated with mutations in the common cytokine receptor γ chain (γc) gene, and characterized by a complete defect of T and natural killer (NK) cells. Gene therapy for SCID-X1 using conventional retroviral (RV) vectors carrying the γc gene results in the successful reconstitution of T cell immunity. However, the high incidence of vector-mediated T cell leukemia, caused by vector insertion near or within cancer-related genes has been a serious problem. In this study, we established a gene therapy model of mouse SCID-X1 using a modified foamy virus (FV) vector expressing human γc. Analysis of vector integration in a human T cell line demonstrated that the FV vector integration sites were significantly less likely to be located within or near transcriptional start sites than RV vector integration sites. To evaluate the therapeutic efficacy, bone marrow cells from γc-knockout (γc-KO) mice were infected with the FV vector and transplanted into γc-KO mice. Transplantation of the FV-treated cells resulted in the successful reconstitution of functionally active T and B cells. These data suggest that FV vectors can be effective and may be safer than conventional RV vectors for gene therapy for SCID-X1. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/23990961/Gene_therapy_model_of_X_linked_severe_combined_immunodeficiency_using_a_modified_foamy_virus_vector_ L2 - http://dx.plos.org/10.1371/journal.pone.0071594 DB - PRIME DP - Unbound Medicine ER -